Congenital heart block

Last updated
Congenital heart block
Pierre.hcs3.jpg
The conduction system of the heart (shown in yellow)
Specialty Medical genetics   OOjs UI icon edit-ltr-progressive.svg
Symptoms slow heart rate [1]
Usual onsetin utero. [1]
Diagnostic method fetal echocardiogram and Doppler and ELISA for the mother [1]
Treatmentfluorinated steroids, beta agonists, IVIG, HCQ, pace maker implantation and maternal plasmapheresis. [1] [2]
Frequency1 child in every 15000-20000 [3]

The congenital heart block (CHB) is the heart block that is diagnosed in fetus (in utero) or within the first 28 days after birth [1] [4] (neonatal period), some studies also include the diagnosis during early childhood to the definition of CHB. [5] It refers to the disorder in the electrical conduction system within the heart muscle, [4] which leads to the failure in pumping the blood efficiently into the aorta and the pulmonary trunk. The result of CHB can be first, second, or third-degree (complete) atrioventricular block (a block in the atrioventricular node) in which no electric signals move from the atrium to the ventricles [5]

Contents

The congenital heart block is a rare disease that affects around 1 child in every 15,000–20,000 births. [3] However, its high mortality (which can be as high as 85% in some severe cases) makes the early diagnosis and intervention very important. [1] CHB can be isolated, where the fetus does not suffer from any other problems, or it can be a result of other diseases either in the child or in the mother. [1]

In most cases, the congenital heart block is associated with other diseases, [5] [4] [1] and therefore, the symptoms vary a lot between patients. However, low heart rate is usually the main clinical presentation that leads to the diagnosis. [6] [5] [1] Also, the treatment varies as well due to the associated diseases and it can be non-invasive (medications given to the pregnant woman or to the child), [2] [7] [1] or a surgery in some cases when the CHB is resulted from anatomical disorders in the heart.

Presentation

The symptoms of the congenital heart block can vary due to the underlying problems that associate / lead to the CHB, and the features of CHB reflects the other manifestations of these diseases. [1]

Bradycardia is usually the first symptom of CHB to be detected in utero. [1] [5] [6] Due to the block in the atrioventricular node, less electric signals move from the sinoatrial node to the bundle of his and its right and left branches, leading to a lower heart rate. The atrioventricular block can be first degree or much more severe like a complete atrioventricular block (third degree). [5] [6] In addition, several changes in the ECG can be detected. [5]

Other manifestations of the congenital heart block can be related to the impact of the maternal autoantibodies in the autoimmune-mediated CHB. Fibrosis of the myocardium (Endocardial fibroelastosis) (EFE) is the obvious one and it occurs due to the damage caused by the maternal autoantibodies to the cardiac tissue of the fetus, and can lead to death in some cases. [5] However, it is not a common feature of CHB. [5]

Another rare symptom that might accompany the autoimmune CHB is the disorder in the valvular function, and this happens due to the damage in the papillary muscles as a result of the maternal autoantibodies. [5]

Causes

In some cases the reason behind CHB remains unknown [1] [4] but in the great majority of affected kids, this disease is associated with the transference of autoantibodies from the mother during gestation or with major cardiac structural abnormalities that lead to a disturbance in the conducting signals in the atrioventricular node. [6] [5] [4] [1] [7] Also, in some rare cases, the congenital heart block was linked with viral infections or treatment with specific medications. [4]

Maternal autoimmune disease

In the autoimmune-mediated congenital heart block, autoantibodies are passively transferred through the placenta during gestation. [7] [6] [5] [4] [1] The mother might be asymptomatic during or after pregnancy but she is usually positive to anti-Ro\SSA or anti-La\SSB antibodies. [5] [4] In this case, the fetus's heart is normally developed and shows no structural malformations. [1] [4] [5] [6] Just like other autoimmune diseases, the autoimmune CHB shows signs of damage resulted from the autoantibodies attacking the normal tissue of the body, inflammation and fibrosis in the fetal heart tissue are the most common ones, mainly in the atrioventricular node. [5] [4] These antibodies lead to irreversible injuries in the atrioventricular node which heavily compromise the efficiency of the electrical conduction system, [6] and this results in around 18% mortality rate and 70% of the live-born kids will need early pacemaker implantation. [8]

Anti-Ro\SSA autoantibody

This autoantibody is found in the serum of the majority of kids with autoimmune CHB, [6] [4] and therefore it is the one mostly linked with this disease. [6] It attacks the proteins Ro52 and Ro60 in the antigen Ro\SSA in the fetal heart tissue. [6] [5] [4]

Anti-La\SSB autoantibody

This antibody attacks the ribonucleoprotein La48 on the surface of the fetal cardiomyocytes, the links between this autoantibody and autoimmune CHB are less strong than the anti-Ro autoantibody and it usually accompanies it in the majority of cases. [6] [4] [5]
Although the autoimmune CHB has a relatively high mortality and morbidity rates, the chance of kids from -mothers positive to anti-Ro\SSA and/or anti-La\SSB antibodies- to suffer from CHB is only around 1-5%, [9] [7] [10] which suggests the existence of other factors to influence the disease such as genetic and environmental factors. [4]

Other autoantibodies

Several autoantibodies were suggested to have links with the autoimmune CHB, mainly the ones associated with the different autoimmune diseases that are common among women (such as the antibodies associated with Systemic lupus erythematosus (SLE), Rheumatoid arthritis, Progressive systemic sclerosis (PSS), and Mixed connective tissue disease). [5] However, the role of these autoantibodies was not studied comprehensively. [5]

Also, some antigens of the fetal heart tissue (apart from the "Ro" and the "La") were studied, but no clear link with the autoimmune CHB was proven. [5]

Congenital cardiac structural abnormalities

The presence of a cardiac structural abnormality is a major determination of the outcome of CHB. [1] Its existence affects the conduction system of the heart and increases the mortality rate and the need for pace-maker implantation. [1]

The cardiac structural diseases that are usually associated with the congenital heart block include the left atrial isomerism with or without atrioventricular septal defect. [1] In addition, levo transpositions of the great arteries can accompany CHB but this is less common than the first one. [1]

These developmental abnormalities can impair the conduction system of the heart by disrupting its anatomical structure. [5]

Diagnosis

There is a difference in diagnosis between low risk pregnancies where mothers do not have (or are not aware of) any autoimmune disease, and the high risk ones where mothers are known to have a specific autoimmune disease and / or are positive to anti Ro/La autoantibodies and / or had a CHB-affected pregnancy previously. [7] [5] [1]

In low risk pregnancies, testing the mothers' serum is not part of the routine prenatal tests. [1] [11] [6] Therefore, the congenital heart block is usually diagnosed during a routine obstetrical ultra sound. [1] The first symptom in most cases is a slow heart rate which can be detected using fetal echocardiogram and Doppler ultra sound techniques between the weeks 18 - 30. [11] [7] [5] [1] The Doppler is very important to assess the level of AV block as well as to check for other cardiac structural abnormalities that might be associated with CHB such as left atrial isomerism, valvular damages and big arteries inversion, [5] [1] while the echocardiogram is useful to detect other complications such as the hydrops fetalis. [1] In the absence of cardiac structural diseases, the second step to confirm the diagnosis is to test the serum of the mother for anti Ro/La autoantibodies using the enzyme-linked immunosorbent assay (ELISA). [7] [1]

In high risk pregnancies, the diagnosis is relatively easier as fetal and maternal screenings are part of the routine monitoring of the pregnancy. [5] [1]

Screening

Although the chance of having kids with CHB in anti Ro/La positive mothers is relatively low (1-5%), [7] [9] [10] it is recommended that all mothers with autoimmune disease to be screened and seek consultation when decide to get pregnant. [1] [4] [5] [11]

For mothers with at least one CHB-affected pregnancy, with 16 - 18% recurrence chance for the directly following pregnancy [11] [1] and an overall 9% chance in following ones, [12] monitoring both the mother and the fetus is crucial. [5]

Treatment

Due to the rarity of this disease, there is a lack of comprehensive and high quality research about the different treatment options, [13] and therefore, no specific treatment plan is followed globally. However, some studies have attempted to outline the most widely accepted approaches in dealing with CHB.[ citation needed ]

Fluorinated steroids

There is no agreement on using fluorinated steroids in treating CHB, and the results of the different studies are contradictory. [13] These steroids (such as dexamethasone) are used when the disease is diagnosed in utero as they can cross the placenta without being deactivated. [7] [1] [2] The main goal of using corticosteroids is to mitigate the inflammation by decreasing the amount of anti Ro/La autoantibodies in the fetal serum. [7] [6] [1] Therefore, they are used in the autoimmune-mediated CHB. Both the mother and the fetus might suffer from their side effects which can include growth problems and adrenal insufficiency. [2]

Beta-adrenergic agonist

Trebutaline and Sulbutamol are among the medications that have been used to treat CHB. [2] They are used mainly to increase the heart rate in fetuses suffering from bradycardia. [2] Although they showed positive results, some patients showed intolerance to their side effects. [2]

Plasmapheresis

Plasma exchange in women positive to anti Ro/La autoantibodies has not been studied thoroughly, but it is suggested to have and effect on the titer of the antibodies in the mother's serum and therefore might have a preventive role. [2] [7] [1]

Intravenous immunoglobulin

Using intravenous immunoglobulin showed some promising results in decreasing the possibility of having CHB's complications such as EFE and cardiomyopathy. [6] [2]

Hydroxychloroquine

Hydroxychloroquine is relatively new approach, but it showed promising results in preventing the inflammation and other injuries result from it such as fibrosis. [6] [2]

Apart from these medications, a pace maker might be needed in around two thirds of the cases, [1] and a procedure might be required when the heart has structural abnormalities.

Outcomes

The outcome of the congenital heart block varies a lot due to several factors, such as the associated diseases, severity of the atrioventricular block, maternal age...etc.

In terms of the severity of the AV block, newborn kids with heart rate lower than 55 bpm have a negative outcome and higher chance to need pace-maker implantation, [1] as well as kids with symptomatic bradycardia such as lower tolerance of exercises. [1]

Isolated CHB has a better prognosis than the one associated with other disorders, [5] [6] [14] [11] the presence of congenital cardiac abnormalities increases the mortality rate. [1] Also, kids presented with hydrops fetalis and / or EFE and / or cardiomyopathy have poor outcome. [14] [11] [6] [5]

Some studies showed a genetic contribution to the autoimmune CHB. [4] [6]

Among anti Ro/La positive women, older ones have higher possibility of having kids with heart block. [12]

Mortality rate in CHB increases with earlier deliveries. [14] [11]

Kids with congenital heart block have higher chance to face health-related problems (such as infections) than other kids. [15] [6]

Epidemiology

The congenital heart block occurs in 1 child in every 15,000 to 20,000 births. [3]

More than 90% of the cases are associated with autoimmune disease and transference of maternal autoantibodies. [16] [14]

Without considering the gender, the age of diagnosis or the associated diseases, mortality rate is around 20%. [11] The majority of CHB-related deaths occur in the first 3 months after birth followed by fetal death, and it is less common to occur after the third month of age. [11]

Mortality rate is very high when the disease is diagnosed prenatally, and declines dramatically with older diagnosis ages. [14]

Around 60% - 70% of the patients will need pace-maker implantation regardless of the age of diagnosis. [14] [11]

The disease seems to affect both males and females equally. [14] [11]

The survival rate is heavily affected by the associated diseases, and it is higher in autoimmune-mediated CHB patients compared to CHB patients with congenital cardiac structural problems. [1] [17]

Recurrence rate: mothers who had pregnancies associated with CHB, have a 16 - 18% chance of having kids with heart block in the following pregnancy. [11] [1]

A study in the United States showed that the vast majority of the affected mothers are of a Caucasian ethnicity, [11] despite the fact that Systemic Lupus Erythematosus (SLE) is more common among minorities. [18]

Table. I: The recurrence rate for pregnancies following the CHB-affected births [11]
OutcomePercentage of Pregnancies
Healthy73%
CHB16%
Fetal Demise2%
Neonatal Death2%

Related Research Articles

<span class="mw-page-title-main">Sjögren syndrome</span> Medical condition

Sjögren syndrome or Sjögren's syndrome is a long-term autoimmune disease that affects the body's moisture-producing glands, and often seriously affects other organ systems, such as the lungs, kidneys, and nervous system.

<span class="mw-page-title-main">Tetralogy of Fallot</span> Type of congenital heart defect

Tetralogy of Fallot (TOF), formerly known as Steno-Fallot tetralogy, is a congenital heart defect characterized by four specific cardiac defects. Classically, the four defects are:

<span class="mw-page-title-main">Antinuclear antibody</span> Autoantibody that binds to contents of the cell nucleus

Antinuclear antibodies are autoantibodies that bind to contents of the cell nucleus. In normal individuals, the immune system produces antibodies to foreign proteins (antigens) but not to human proteins (autoantigens). In some cases, antibodies to human antigens are produced.

<span class="mw-page-title-main">Hashimoto's thyroiditis</span> Autoimmune disease

Hashimoto's thyroiditis, also known as chronic lymphocytic thyroiditis and Hashimoto's disease, is an autoimmune disease in which the thyroid gland is gradually destroyed. Early on, symptoms may not be noticed. Over time, the thyroid may enlarge, forming a painless goiter. Some people eventually develop hypothyroidism with accompanying weight gain, fatigue, constipation, depression, hair loss, and general pains. After many years the thyroid typically shrinks in size. Potential complications include thyroid lymphoma. Furthermore, because it is common for untreated patients of Hashimoto's to develop hypothyroidism, further complications can include, but are not limited to, high cholesterol, heart disease, heart failure, high blood pressure, myxedema, and potential pregnancy problems.

<span class="mw-page-title-main">Congenital heart defect</span> Defect in the structure of the heart that is present at birth

A congenital heart defect (CHD), also known as a congenital heart anomaly, congenital cardiovascular malformation, and congenital heart disease, is a defect in the structure of the heart or great vessels that is present at birth. A congenital heart defect is classed as a cardiovascular disease. Signs and symptoms depend on the specific type of defect. Symptoms can vary from none to life-threatening. When present, symptoms are variable and may include rapid breathing, bluish skin (cyanosis), poor weight gain, and feeling tired. CHD does not cause chest pain. Most congenital heart defects are not associated with other diseases. A complication of CHD is heart failure.

<span class="mw-page-title-main">Hemolytic disease of the newborn</span> Fetal and neonatal alloimmune blood condition

Hemolytic disease of the newborn, also known as hemolytic disease of the fetus and newborn, HDN, HDFN, or erythroblastosis foetalis, is an alloimmune condition that develops in a fetus at or around birth, when the IgG molecules produced by the mother pass through the placenta. Among these antibodies are some which attack antigens on the red blood cells in the fetal circulation, breaking down and destroying the cells. The fetus can develop reticulocytosis and anemia. The intensity of this fetal disease ranges from mild to very severe, and fetal death from heart failure can occur. When the disease is moderate or severe, many erythroblasts are present in the fetal blood, earning these forms of the disease the name erythroblastosis fetalis.

<span class="mw-page-title-main">Hydrops fetalis</span> Human disease of fetuses

Hydrops fetalis or hydrops foetalis is a condition in the fetus characterized by an accumulation of fluid, or edema, in at least two fetal compartments. By comparison, hydrops allantois or hydrops amnion is an accumulation of excessive fluid in the allantoic or amniotic space, respectively.

Extractable nuclear antigens (ENAs) are over 100 different soluble cytoplasmic and nuclear antigens. They are known as "extractable" because they can be removed from cell nuclei using saline and represent six main proteins: Ro, La, Sm, RNP, Scl-70, Jo1. Most ENAs are part of spliceosomes or nucleosomes complexes and are a type of small nuclear ribonucleoprotein (snRNPS). The location in the nucleus and association with spliceosomes or nucleosomes results in these ENAs being associated with additional RNA and proteins such as polymerases. This quality of ENAs often makes it difficult to purify and quantify their presence for clinical use.

<span class="mw-page-title-main">Maternal–fetal medicine</span> Branch of medicine

Maternal–fetal medicine (MFM), also known as perinatology, is a branch of medicine that focuses on managing health concerns of the mother and fetus prior to, during, and shortly after pregnancy.

<span class="mw-page-title-main">TRIM21</span> Protein-coding gene in the species Homo sapiens

Tripartite motif-containing protein 21, also known as E3 ubiquitin-protein ligase TRIM21, is a protein that in humans is encoded by the TRIM21 gene. Alternatively spliced transcript variants for this gene have been described but the full-length nature of only one has been determined. It is expressed in most human tissues.

Fetal echocardiography, or Fetal echocardiogram, is the name of the test used to diagnose cardiac conditions in the fetal stage. Cardiac defects are amongst the most common birth defects. Their diagnosis is important in the fetal stage as it might help provide an opportunity to plan and manage the baby as and when the baby is born. Not all pregnancies need to undergo fetal echo.

<span class="mw-page-title-main">Anti-dsDNA antibodies</span> Group of anti-nuclear antibodies

Anti-double stranded DNA (Anti-dsDNA) antibodies are a group of anti-nuclear antibodies (ANA) the target antigen of which is double stranded DNA. Blood tests such as enzyme-linked immunosorbent assay (ELISA) and immunofluorescence are routinely performed to detect anti-dsDNA antibodies in diagnostic laboratories. They are highly diagnostic of systemic lupus erythematosus (SLE) and are implicated in the pathogenesis of lupus nephritis.

Neonatal lupuserythematosus is an autoimmune disease in an infant born to a mother with anti-Ro/SSA and with or without anti-La/SSB antibodies. The disease most commonly presents with a rash resembling subacute cutaneous lupus erythematosus and can have systemic abnormalities such as complete heart block or hepatosplenomegaly. Neonatal lupus is usually benign and self-limited. Many of the clinical manifestations are transient, but certain heart problems can be permanent. Diagnosis is based on maternal antibodies and clinical manifestations. Treatment and management is mainly supportive and focused on preventing complete heart block if possible.

<span class="mw-page-title-main">Lupus</span> Human autoimmune disease

Lupus, technically known as systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. Symptoms vary among people and may be mild to severe. Common symptoms include painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, swollen lymph nodes, feeling tired, and a red rash which is most commonly on the face. Often there are periods of illness, called flares, and periods of remission during which there are few symptoms.

Thyroid disease in pregnancy can affect the health of the mother as well as the child before and after delivery. Thyroid disorders are prevalent in women of child-bearing age and for this reason commonly present as a pre-existing disease in pregnancy, or after childbirth. Uncorrected thyroid dysfunction in pregnancy has adverse effects on fetal and maternal well-being. The deleterious effects of thyroid dysfunction can also extend beyond pregnancy and delivery to affect neurointellectual development in the early life of the child. Due to an increase in thyroxine binding globulin, an increase in placental type 3 deioidinase and the placental transfer of maternal thyroxine to the fetus, the demand for thyroid hormones is increased during pregnancy. The necessary increase in thyroid hormone production is facilitated by high human chorionic gonadotropin (hCG) concentrations, which bind the TSH receptor and stimulate the maternal thyroid to increase maternal thyroid hormone concentrations by roughly 50%. If the necessary increase in thyroid function cannot be met, this may cause a previously unnoticed (mild) thyroid disorder to worsen and become evident as gestational thyroid disease. Currently, there is not enough evidence to suggest that screening for thyroid dysfunction is beneficial, especially since treatment thyroid hormone supplementation may come with a risk of overtreatment. After women give birth, about 5% develop postpartum thyroiditis which can occur up to nine months afterwards. This is characterized by a short period of hyperthyroidism followed by a period of hypothyroidism; 20–40% remain permanently hypothyroid.

<span class="mw-page-title-main">Anti-SSA/Ro autoantibodies</span> Type of anti-nuclear autoantibodies

Anti-SSA autoantibodies are a type of anti-nuclear autoantibodies that are associated with many autoimmune diseases, such as systemic lupus erythematosus (SLE), SS/SLE overlap syndrome, subacute cutaneous lupus erythematosus (SCLE), neonatal lupus and primary biliary cirrhosis. They are often present in Sjögren's syndrome (SS). Additionally, Anti-Ro/SSA can be found in other autoimmune diseases such as systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), rheumatoid arthritis (RA), and mixed connective tissue disease (MCTD), and are also associated with heart arrhythmia.

Lupus and pregnancy can present some particular challenges for both mother and child.

Antithyroid autoantibodies (or simply antithyroid antibodies) are autoantibodies targeted against one or more components on the thyroid. The most clinically relevant anti-thyroid autoantibodies are anti-thyroid peroxidase antibodies (anti-TPO antibodies, TPOAb), thyrotropin receptor antibodies (TRAb) and thyroglobulin antibodies (TgAb). TRAb's are subdivided into activating, blocking and neutral antibodies, depending on their effect on the TSH receptor. Anti-sodium/iodide (Anti–Na+/I−) symporter antibodies are a more recent discovery and their clinical relevance is still unknown. Graves' disease and Hashimoto's thyroiditis are commonly associated with the presence of anti-thyroid autoantibodies. Although there is overlap, anti-TPO antibodies are most commonly associated with Hashimoto's thyroiditis and activating TRAb's are most commonly associated with Graves' disease. Thyroid microsomal antibodies were a group of anti-thyroid antibodies; they were renamed after the identification of their target antigen (TPO).

<span class="mw-page-title-main">High-risk pregnancy</span> Medical condition

A high-risk pregnancy is one where the mother or the fetus has an increased risk of adverse outcomes compared to uncomplicated pregnancies. No concrete guidelines currently exist for distinguishing “high-risk” pregnancies from “low-risk” pregnancies; however, there are certain studied conditions that have been shown to put the mother or fetus at a higher risk of poor outcomes. These conditions can be classified into three main categories: health problems in the mother that occur before she becomes pregnant, health problems in the mother that occur during pregnancy, and certain health conditions with the fetus.

Eldad Ben-Chetrit is a professor of Medicine, former Head of the Department of Medicine and former director of the Rheumatology unit (2009-2017) at the Hadassah-Hebrew University Medical Center in Jerusalem. He was a visiting professor at the Oklahoma Medical Research Foundation (1996), at the Biochemistry Department, Stanford University (2004), and at the Gaslini Children Hospital, University of Genoa, Italy, and the Tropical Medicine Clinic, University of Heidelberg, Germany (2016).

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 Friedman, DM; Duncanson, LJ; Glickstein, J; Buyon, JP (2003). "A review of congenital heart block". Images in Paediatric Cardiology. 5 (3): 36–48. ISSN   1729-441X. PMC   3232542 . PMID   22368629.
  2. 1 2 3 4 5 6 7 8 9 10 Saxena, Amit; Izmirly, Peter M.; Mendez, Barbara; Buyon, Jill P.; Friedman, Deborah M. (November 2014). "Prevention and treatment in utero of autoimmune-associated congenital heart block". Cardiology in Review. 22 (6): 263–267. doi:10.1097/CRD.0000000000000026. ISSN   1538-4683. PMC   4539276 . PMID   25050975.
  3. 1 2 3 Michaëlsson, M.; Engle, M. A. (1972). "Congenital complete heart block: an international study of the natural history". Cardiovascular Clinics. 4 (3): 85–101. ISSN   0069-0384. PMID   4273004.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Ambrosi, Aurélie; Wahren-Herlenius, Marie (2012-04-26). "Congenital heart block: evidence for a pathogenic role of maternal autoantibodies". Arthritis Research & Therapy. 14 (2): 208. doi:10.1186/ar3787. ISSN   1478-6362. PMC   3446439 . PMID   22546326.
  5. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Brito-Zerón, Pilar; Izmirly, Peter M.; Ramos-Casals, Manuel; Buyon, Jill P.; Khamashta, Munther A. (May 2015). "The clinical spectrum of autoimmune congenital heart block". Nature Reviews. Rheumatology. 11 (5): 301–312. doi:10.1038/nrrheum.2015.29. ISSN   1759-4804. PMC   5551504 . PMID   25800217.
  6. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Wainwright, Benjamin; Bhan, Rohit; Trad, Catherine; Cohen, Rebecca; Saxena, Amit; Buyon, Jill; Izmirly, Peter (2019-10-08). "Autoimmune-mediated congenital heart block". Best Practice & Research Clinical Obstetrics & Gynaecology. 64: 41–51. doi:10.1016/j.bpobgyn.2019.09.001. ISSN   1521-6934. PMID   31685414.
  7. 1 2 3 4 5 6 7 8 9 10 11 Friedman, Deborah M.; Rupel, Ann; Glickstein, Julie; Buyon, Jill P. (June 2002). "Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective". Indian Journal of Pediatrics. 69 (6): 517–522. doi:10.1007/bf02722656. ISSN   0019-5456. PMID   12139139. S2CID   44783535.
  8. ↑ Izmirly Peter M.; Saxena Amit; Kim Mimi Y.; Wang Dan; Sahl Sara K.; Llanos Carolina; Friedman Deborah; Buyon Jill P. (2011-11-01). "Maternal and Fetal Factors Associated With Mortality and Morbidity in a Multi–Racial/Ethnic Registry of Anti-SSA/Ro–Associated Cardiac Neonatal Lupus". Circulation. 124 (18): 1927–1935. doi:10.1161/CIRCULATIONAHA.111.033894. PMC   3206147 . PMID   21969015.
  9. 1 2 Buyon, J. P.; Kim, M. Y.; Copel, J. A.; Friedman, D. M. (August 2001). "Anti-Ro/SSA antibodies and congenital heart block: necessary but not sufficient". Arthritis and Rheumatism. 44 (8): 1723–1727. doi:10.1002/1529-0131(200108)44:8<1723::AID-ART305>3.0.CO;2-0. ISSN   0004-3591. PMID   11508420.
  10. 1 2 Brucato, A.; Frassi, M.; Franceschini, F.; Cimaz, R.; Faden, D.; Pisoni, M. P.; Muscarà, M.; Vignati, G.; Stramba-Badiale, M.; Catelli, L.; Lojacono, A. (August 2001). "Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women". Arthritis and Rheumatism. 44 (8): 1832–1835. doi: 10.1002/1529-0131(200108)44:8<1832::AID-ART320>3.0.CO;2-C . ISSN   0004-3591. PMID   11508435.
  11. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Buyon, Jill P.; Hiebert, Rudi; Copel, Joshua; Craft, Joseph; Friedman, Deborah; Katholi, Margaret; Lee, Lela A.; Provost, Thomas T.; Reichlin, Morris; Rider, Lisa; Rupel, Ann (1998-06-01). "Autoimmune-Associated Congenital Heart Block: Demographics, Mortality, Morbidity and Recurrence Rates Obtained From a National Neonatal Lupus Registry". Journal of the American College of Cardiology. 31 (7): 1658–1666. doi: 10.1016/S0735-1097(98)00161-2 . ISSN   0735-1097. PMID   9626848.
  12. 1 2 Ambrosi, Aurélie; Salomonsson, Stina; Eliasson, Håkan; Zeffer, Elisabeth; Skog, Amanda; Dzikaite, Vijole; Bergman, Gunnar; Fernlund, Eva; Tingström, Joanna; Theander, Elke; Rydberg, Annika (2012-03-01). "Development of heart block in children of SSA/SSB-autoantibody-positive women is associated with maternal age and displays a season-of-birth pattern". Annals of the Rheumatic Diseases. 71 (3): 334–340. doi:10.1136/annrheumdis-2011-200207. ISSN   0003-4967. PMID   21953338. S2CID   8446668.
  13. 1 2 Brucato, Antonio; Tincani, Angela; Fredi, Micaela; Breda, Silvia; Ramoni, Veronique; Morel, Nathalie; Costedoat-Chalumeau, Nathalie (2017-11-01). "Should we treat congenital heart block with fluorinated corticosteroids?". Autoimmunity Reviews. 16 (11): 1115–1118. doi:10.1016/j.autrev.2017.09.005. ISSN   1568-9972. PMID   28899797.
  14. 1 2 3 4 5 6 7 Jaeggi, Edgar T; Hamilton, Robert M; Silverman, Earl D; Zamora, Samuel A; Hornberger, Lisa K (2002-01-02). "Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block: A single institution's experience of 30 years". Journal of the American College of Cardiology. 39 (1): 130–137. doi:10.1016/S0735-1097(01)01697-7. ISSN   0735-1097. PMID   11755298.
  15. ↑ Mofors, Johannes; Eliasson, Håkan; Ambrosi, Aurelie; Salomonsson, Stina; Skog, Amanda; Fored, Michael; Ekbom, Anders; Bergman, Gunnar; Sonesson, Sven-Erik; Wahren-Herlenius, Marie (2019-05-01). "Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero". Annals of the Rheumatic Diseases. 78 (5): 696–703. doi:10.1136/annrheumdis-2018-214406. ISSN   0003-4967. PMID   30808622. S2CID   73476814.
  16. ↑ Chameides, L.; Truex, R. C.; Vetter, V.; Rashkind, W. J.; Galioto, F. M.; Noonan, J. A. (1977-12-01). "Association of maternal systemic lupus erythematosus with congenital complete heart block". The New England Journal of Medicine. 297 (22): 1204–1207. doi:10.1056/NEJM197712012972203. ISSN   0028-4793. PMID   917056.
  17. ↑ Kertesz, N. J.; Fenrich, A. L.; Friedman, R. A. (1997). "Congenital complete atrioventricular block". Texas Heart Institute Journal. 24 (4): 301–307. ISSN   0730-2347. PMC   325472 . PMID   9456483.
  18. ↑ Fessel, W. Jeffrey (1974-12-01). "Systemic Lupus Erythematosus in the Community: Incidence, Prevalence, Outcome, and First Symptoms; the High Prevalence in Black Women". Archives of Internal Medicine. 134 (6): 1027–1035. doi:10.1001/archinte.1974.00320240061006. ISSN   0003-9926. PMID   4433183.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.